Vertex Pharmaceuticals lost market share due to illegal knockoffs of its medicines.
2 reports, 1 independent
Updated Aug 24
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vertex Pharmaceuticals lost market share due to illegal knockoffs of its medicines.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Siona's trial failure allowed Vertex dominance to surge.Sub-event
Illegal knockoffs caused Vertex Pharmaceuticals to lose market share.1 source
Keep exploring
The entities involved
-
Vertex Pharmaceuticals
American pharmaceutical company
Related events
- Morgan Stanley began research coverage on Vertex Pharmaceuticals, raising its target price and giving it an overweight rating, alongside institutional filings.
- Vertex Pharmaceuticals presented updates at a Wells Fargo conference on September 12, 2026.
- Goldman Sachs updated its top stock picks, removing Interactive Brokers and adding Vertex Pharmaceuticals.
Coverage
Newest first; wire copies grouped- Motley FoolThis Magnificent S&P 500 Dividend Stock Is Down 18% -- Time to Buy? Vertex Pharmaceuticals has faced clinical trial disappointments, and illegal competition for some medicines. Despite these roadbloc
- Unknown outlet